Jun 20, 2023 / 11:30AM GMT
Operator
Welcome to today's press conference with Camurus. (Operator Instructions) Now I'll hand the conference over to CEO and President, Fred Tiberg. Please go ahead.
Fredrik Tiberg - Camurus AB(publ)-President - CEO, CSO & Director
Thank you so much, (inaudible), and hi, everyone, and welcome to today's conference call, where we will present the top line results from our pivotal acromegaly Phase III trial ACROINNOVA, and we're very pleased to do that today.
We -- before going into the presentation, please note our forward-looking statements. As usual, we will start this presentation with a short summary of the results, then our Chief Medical Officer; Alberto Pedroncelli will give a brief introduction to acromegaly octreotide SC depot and also to himself. Yes, then we will have a more detailed presentation of the top line results, followed by next steps and Q&A.
So with me in the call, I have Alberto, of course, here; and then also our VP Clinical Development and Pharmacovigilance, Agneta Svedberg.
Camurus AB Special Call Transcript
Jun 20, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers